Evidence map›Paper›PMID 25928089›Full record

ArticleStem cell research & therapy2015

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Christina Katanov, Shalom Lerrer, Yulia Liubomirski, Leonor Leider-Trejo, Tsipi Meshel, Jair Bar, Rotem Feniger-Barish, Iris Kamer, Gali Soria-Artzi, Hadar Kahani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 144 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Christina KatanovDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. christina.katanov@weizmann.ac.il.
Shalom LerrerDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. slerrer@gmail.com.
Yulia LiubomirskiDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. yulialiub@gmail.com.
Leonor Leider-TrejoDepartment of Pathology, Tel Aviv Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv, 64239, Israel. treleox2@yahoo.com.
Tsipi MeshelDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. tzipi@post.tau.ac.il.
Jair BarInstitute of Oncology, Sheba Medical Center, Tel-Hashomer, Ramat Gan, 5262100, Israel. bar.jair@gmail.com.
Rotem Feniger-BarishInstitute of Oncology, Sheba Medical Center, Tel-Hashomer, Ramat Gan, 5262100, Israel. rotemfe@gmail.com.
Iris KamerInstitute of Oncology, Sheba Medical Center, Tel-Hashomer, Ramat Gan, 5262100, Israel. iris.kamer@gmail.com.
Gali Soria-ArtziDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. galisoria@gmail.com.
Hadar KahaniDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. kahanihadar@gmail.com.
Debabrata BanerjeeDepartment of Medicine and Pharmacology, Robert Wood Johnson Medical School and Graduate School of Biomedical Sciences, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA. banerjed@cinj.rutgers.edu.
Adit Ben-BaruchDepartment of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel. aditbb@tauex.tau.ac.il.
Tel Aviv University · ILSheba Medical Center · ILRutgers, The State University of New Jersey · USTel Aviv Sourasky Medical Center · ILWeizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBreast cancer progression is promoted by stromal cells that populate the tumors, including cancer-associated fibroblasts (CAFs) and mesenchymal stem/stromal cells (MSCs). The activities of CAFs and MSCs in breast cancer are integrated within an intimate inflammatory tumor microenvironment (TME) that includes high levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β). Here, we identified the impact of TNF-α and IL-1β on the inflammatory phenotype of CAFs and MSCs by determining the expression of inflammatory chemokines that are well-characterized as pro-tumorigenic in breast cancer: CCL2 (MCP-1), CXCL8 (IL-8) and CCL5 (RANTES).

methodsChemokine expression was determined in breast cancer patient-derived CAFs by ELISA and in patient biopsies by immunohistochemistry. Chemokine levels were determined by ELISA in (1) human bone marrow-derived MSCs stimulated by tumor conditioned media (Tumor CM) of breast tumor cells (MDA-MB-231 and MCF-7) at the end of MSC-to-CAF-conversion process; (2) Tumor CM-derived CAFs, patient CAFs and MSCs stimulated by TNF-α (and IL-1β). The roles of AP-1 and NF-κB in chemokine secretion were analyzed by Western blotting and by siRNAs to c-Jun and p65, respectively. Migration of monocytic cells was determined in modified Boyden chambers.

resultsTNF-α (and IL-1β) induced the release of CCL2, CXCL8 and CCL5 by MSCs and CAFs generated by prolonged stimulation of MSCs with Tumor CM of MDA-MB-231 and MCF-7 cells. Patient-derived CAFs expressed CCL2 and CXCL8, and secreted CCL5 following TNF-α (and IL-1β) stimulation. CCL2 was expressed in CAFs residing in proximity to breast tumor cells in biopsies of patients diagnosed with invasive ductal carcinoma. CCL2 release by TNF-α-stimulated MSCs was mediated by TNF-RI and TNF-RII, through the NF-κB but not via the AP-1 pathway. Exposure of MSCs to TNF-α led to potent CCL2-induced migration of monocytic cells, a process that may yield pro-cancerous myeloid infiltrates in breast tumors.

conclusionsOur novel results emphasize the important roles of inflammation-stroma interactions in breast cancer, and suggest that NF-κB may be a potential target for inhibition in tumor-adjacent stromal cells, enabling improved tumor control in inflammation-driven malignancies.

Indexed as

Blotting, WesternBone Marrow CellsBreast NeoplasmsCell Line, TumorCell MovementChemokine CCL2Chemokine CCL5Culture Media, ConditionedFemaleFibroblastsHumansInterleukin-1betaInterleukin-8JNK Mitogen-Activated Protein KinasesMCF-7 CellsMesenchymal Stem CellsChemokine CCL2Chemokine CCL5Culture Media, ConditionedInterleukin-1betaInterleukin-8JNK Mitogen-Activated Protein KinasesNF-kappa BTranscription Factor RelATumor Necrosis Factor-alpha

Identifiers

PMID25928089
PMCPMC4469428
OpenAlexW2138076903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.